These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 11812254)

  • 1. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs.
    Gualtieri F; Manetti D; Romanelli MN; Ghelardini C
    Curr Pharm Des; 2002; 8(2):125-38. PubMed ID: 11812254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-pyrrolidinone moiety is not critical for the cognition-enhancing activity of piracetam-like drugs.
    Scapecchi S; Martelli C; Ghelardini C; Guandalini L; Martini E; Gualtieri F
    Farmaco; 2003 Sep; 58(9):715-22. PubMed ID: 13679165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2012; 32(4):793-887. PubMed ID: 22886028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2013; 33(3):547-658. PubMed ID: 23042218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive enhancers (nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. disease-modifying drugs.
    Froestl W; Pfeifer A; Muhs A
    J Alzheimers Dis; 2013; 34(1):1-114. PubMed ID: 23186990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piracetam for dementia or cognitive impairment.
    Flicker L; Grimley Evans J
    Cochrane Database Syst Rev; 2000; (2):CD001011. PubMed ID: 10796585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
    Tariska P; Paksy A
    Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.
    Malykh AG; Sadaie MR
    Drugs; 2010 Feb; 70(3):287-312. PubMed ID: 20166767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of 1-azabicyclo[3.3.0]octane derivatives and their effects as piracetam-like nootropics.
    Oka M; Matsumoto Y; Hirooka K; Suzuki T
    Chem Pharm Bull (Tokyo); 2000 Aug; 48(8):1121-4. PubMed ID: 10959574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive enhancers (Nootropics). Part 1: drugs interacting with receptors. Update 2014.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2014; 41(4):961-1019. PubMed ID: 24898652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014.
    Froestl W; Muhs A; Pfeifer A
    J Alzheimers Dis; 2014; 42(1):1-68. PubMed ID: 24903780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nootropics: preclinical results in the light of clinical effects; comparison with tacrine.
    Mondadori C
    Crit Rev Neurobiol; 1996; 10(3-4):357-70. PubMed ID: 8978986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piracetam treatment in patients with cognitive impairment.
    Rao MG; Holla B; Varambally S; Raveendranathan D; Venkatasubramanian G; Gangadhar BN
    Gen Hosp Psychiatry; 2013; 35(4):451.e5-6. PubMed ID: 22763000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piracetam--an old drug with novel properties?
    Winnicka K; Tomasiak M; Bielawska A
    Acta Pol Pharm; 2005; 62(5):405-9. PubMed ID: 16459490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between psychological and pharmacological treatment in cognitive impairment.
    Deberdt W
    Life Sci; 1994; 55(25-26):2057-66. PubMed ID: 7997065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and nootropic activity of new analogues of sunifiram and sapunifiram, two potent cognition-enhancers.
    Martini E; Salvicchi A; Ghelardini C; Manetti D; Dei S; Guandalini L; Martelli C; Melchiorre M; Cellai C; Scapecchi S; Teodori E; Romanelli MN
    Bioorg Med Chem; 2009 Nov; 17(21):7606-14. PubMed ID: 19786353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PASS-predicted design, synthesis and biological evaluation of cyclic nitrones as nootropics.
    Marwaha A; Goel RK; Mahajan MP
    Bioorg Med Chem Lett; 2007 Sep; 17(18):5251-5. PubMed ID: 17643300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders.
    Vernon MW; Sorkin EM
    Drugs Aging; 1991 Jan; 1(1):17-35. PubMed ID: 1794001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piracetam for dementia or cognitive impairment.
    Flicker L; Grimley Evans G
    Cochrane Database Syst Rev; 2001; (2):CD001011. PubMed ID: 11405971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piracetam and TRH analogues antagonise inhibition by barbiturates, diazepam, melatonin and galanin of human erythrocyte D-glucose transport.
    Naftalin RJ; Cunningham P; Afzal-Ahmed I
    Br J Pharmacol; 2004 Jun; 142(3):594-608. PubMed ID: 15148255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.